Immunohistochemical Study of O-GlcNAcylation in Human Skin Tumors

O‐GlcNAcylation in oral squamous cell carcinoma

“…A lack of enhanced O ‐GlcNAc levels or OGT overexpression in OSCC or oral cancer cells suggests that PTM by O ‐GlcNAcylation may not be involved in oral carcinogenesis. These results were inconsistent with hyper‐ O ‐GlcNAcylation and OGT overexpression in squamous cell carcinoma of the larynx, the esophagus, and the skin, suggesting distinct tissue‐specific PTMs. However, our findings are still similar to no differences in O ‐GlcNAc immunostaining intensities between liver or pancreatic cancer and their adjacent normal tissues .…”

“…Besides phosphorylation, addition of N ‐acetylglucosamine (GlcNAc) at the hydroxyl groups of serine and/or threonine residues, known as O ‐linked β‐ N ‐acetylglucosamine ( O ‐GlcNAc) or O ‐GlcNAcylation, of cytosolic and nuclear proteins functioning in various intracellular processes, such as transcription, cell cycle regulation, epigenetic control of gene expression in response to nutrients and stress, is involved with cancer cell biology . Increased O ‐GlcNAcylation levels are reported in several solid mass tumors, such as breast cancer, prostate cancer, cholangiocarcinoma, laryngeal and esophageal squamous cell carcinoma, and skin cancer, and are associated with tumor progression, metastasis, recurrence, and poor survival rates . Both EGFR and Akt can be modified by O ‐GlcNAcylation in addition to phosphorylation.…”